betic subjects has gradually increased, and the proportion of obesity (BMI ≥ 25 kg/m 2 ) and abdominal obesity are 48.6% and 58.9%, respectively. 1 The first line treatment of obesity is a combination of a low calorie diet, increased physical activity, and behavioral therapy. However, it is very difficult for obese subjects to reduce and maintain their weight by life-style modification alone. Several kinds of newly developed antidiabetic medications showed useful advantages in obese diabetic patients. Such patients show not only reduced hypoglycemia, but also moderate effects of weight reduction and decrease in blood pressure.
Cho et al. 2 retrospectively investigated the effect of dapagliflozin on body weight reduction in Korean subjects with type 2 diabetes mellitus (T2DM). Although the study had no control group, metformin based-combination treatment of dapagliflozin with other classes of oral hypoglycemic agents in Korean patients with T2DM
showed comparable efficacy of body weight reduction, blood pressure lowering, and antihyperglycemic effects to a previous report 3 and few adverse events. However, the number of subjects was too natriuresis. However, SGLT2i-associated weight loss is less than the amount predicted based on urinary glucose excretion. 6 This might be due to the role of SGLT1 upregulation in renal reabsorption of glucose, which can decrease weight loss, but was not inhibited by SGLT2is 7 or might be more complicated than we currently expect.
Meta-analysis showed that all named SGLT2is in clinical trials significantly reduced body weight, and the best reduction was achieved when the SGLT2i was used alone or in combination with metformin. 8 For example, compared with placebo, dosage-dependent body weight reduction by dapagliflozin treatment was ~2.24 kg. 8 Although the amount of weight loss by SGLT2i was not sufficient to consider the material as a primary anti-obesity drug, the finding that some portion of SGLT2i-treated subjects experienced ≥ 3% body weight reduction cannot be ignored. 9 In addition, recent animal studies have reported encouraging results on the protective effects against complications of obesity such as nonalcoholic fatty liver disease. Empagliflozin, ipragliflozin, and dapagliflozin ameliorated liver steatosis and slowed the progression of liver fibrosis in obese diabetic animals. [10] [11] [12] Moreover, a growing body of evidence has suggested that SGLT2 inhibition affords renal protection by attenuation of glomerular hyperfiltration and long-term glomerular damage. 
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